Sanofi and Regeneron acknowledged that testing their inflammatory disease blockbuster Dupixent in chronic obstructive pulmonary disease (COPD) was likely to be high-risk when they launched phase 3 ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD ...

"FDA greenlights Regeneron’s Dupixent for the treatment of COPD" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand.

Several months before the European Medicines Agency’s (EMA) and FDA’s approval, Sanofi and Regeneron’s Dupixent showed promising evidence of its benefit to COPD patients, namely a reduction ...

President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “With millions of people in industrialized areas worldwide facing increased risk for developing COPD ...

Third quarter 2024 revenues increased 11% to $3.72 billion versus third quarter 2023Third quarter 2024 Dupixent® global net sales(recorded by ...

President and Chief Scientific Officer at Regeneron, and a principal inventor of Dupixent. “With millions of people in industrialized areas worldwide facing increased risk for developing COPD ...

Regeneron recently secured approval for Dupixent in treating Chronic Obstructive Pulmonary Disease (COPD) in the European Union, with a pending approval decision in the United States expected in the ...

President and Chief Executive Officer of Regeneron. "Over one million patients around the globe are currently being treated with Dupixent, with more to come following the approvals for COPD in the ...

Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth indication — chronic obstructive pulmonary disease (COPD) — in the United ...